AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17630037 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of strategy B with strategy C
Number of subjects: 2135
Study 15001463 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (15 g)
Number of subjects: 20
Study 15001463 — intervention group
Group type: COMPARATOR
Intervention: Noncaffeinated coffee (15 g) (control)
Number of subjects: 20
Study 11157320 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (0.9% Ca by wt, 0.9 g Ca/d)
Number of subjects: 10
Study 11157320 — intervention group
Group type: COMPARATOR
Intervention: Control diet (without calcium supplementation)
Number of subjects: 10
Study 9621290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotic patients
Number of subjects: 8
Study 9621290 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 8
Study 7918290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral albendazole 15 mg/kg once daily for 1 month
Number of subjects: 24
Study 7918290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3049266 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride 0.5 mg
Number of subjects: 3
Study 3049266 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride 1.0 mg
Number of subjects: 3
Study 3049266 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride 0.25 mg
Number of subjects: 3
Study 29182895 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill running training (DRG)
Number of subjects: 18
Study 29182895 — intervention group
Group type: COMPARATOR
Intervention: Level running training (LRG)
Number of subjects: 18
Study 28036334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (selective hERG potassium channel blocker)
Number of subjects: 0
Study 28036334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (alone) and in combination with lidocaine and mexiletine (late sodium current blockers)
Number of subjects: 0
Study 24662130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-adriamycin-paclitaxel (TAP) neoadjuvant chemotherapy for 3 cycles
Number of subjects: 30
Study 22375970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 219
Study 22375970 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 219
Study 20044749 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement per kilogram of lean body mass (LBM) (2.5 mcg/kg LBM per day)
Number of subjects: 0
Study 20044749 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement per kilogram of body weight (1.6 mcg/kg body weight per day)
Number of subjects: 0
Study 20044749 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical replacement of thyroxine
Number of subjects: 0
Study 20044749 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement based on LBM
Number of subjects: 0
Study 20044749 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose regimens based on body weight
Number of subjects: 0
Study 18557262 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC)
Number of subjects: 66
Study 18557262 — intervention group
Group type: COMPARATOR
Intervention: Standard nursery care
Number of subjects: 66
Study 16398378 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Classic
Number of subjects: 3
Study 16398378 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Unique
Number of subjects: 3
Study 16398378 — intervention group
Group type: EXPERIMENTAL
Intervention: SoftSeal
Number of subjects: 3
Study 12869973 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus
Number of subjects: 36
Study 12869973 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 36
Study 12869973 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite
Number of subjects: 36
Study 12869973 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT
Number of subjects: 36
Study 12869973 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 36
Study 12869973 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L Pop
Number of subjects: 36
Study 10501340 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised exercise renal rehabilitation program (group A) consisting of three weekly sessions of aerobic training
Number of subjects: 38
Study 10501340 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise program at home (group B)
Number of subjects: 38
Study 10501340 — intervention group
Group type: COMPARATOR
Intervention: No training (group C, control)
Number of subjects: 38
Study 8601248 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with laser assistance
Number of subjects: 82
Study 8601248 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty alone
Number of subjects: 82
Study 2027146 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of the P6 antiemetic point (Neiguan) using a battery-operated TENS machine (15 Hz) for 5 minutes every 2 hours.
Number of subjects: 100
Study 2027146 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of Sea Bands every 2 hours.
Number of subjects: 100
Study 2027146 — intervention group
Group type: COMPARATOR
Intervention: Invasive acupuncture (not directly tested in this study).
Number of subjects: 100
Study 7293943 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 69
Study 30782974 — intervention group
Group type: EXPERIMENTAL
Intervention: Novelty-facilitated extinction
Number of subjects: 0
Study 30782974 — intervention group
Group type: COMPARATOR
Intervention: Standard extinction
Number of subjects: 0
Study 29903274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention with eggs and milk (200 g school milk and 50 g halogen eggs per school day)
Number of subjects: 672
Study 29903274 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 672
Study 27087059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (4 or 8 mg/kg IV) + methotrexate
Number of subjects: 1149
Study 27087059 — intervention group
Group type: COMPARATOR
Intervention: Placebo + methotrexate
Number of subjects: 1149
Study 27087059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab + methotrexate
Number of subjects: 1149
Study 25144847 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial pain catheter with ropivacaine (n=33)
Number of subjects: 100
Study 25144847 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative administration of a single dose of ropivacaine (n=33)
Number of subjects: 100
Study 25144847 — intervention group
Group type: COMPARATOR
Intervention: Conservative pain therapy (n=34)
Number of subjects: 100
Study 21930244 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month weight loss intervention
Number of subjects: 189
Study 21930244 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 189
Study 18951540 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1,800 pulses; 1 Hz rate)
Number of subjects: 10
Study 18951540 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 10
Study 18368870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronisation Therapy (CRT)
Number of subjects: 0
Study 18368870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI) techniques
Number of subjects: 0
Study 15120371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal hyperthermic chemotherapy (IPHC) with mitomycin C
Number of subjects: 34
Study 15120371 — intervention group
Group type: COMPARATOR
Intervention: Radical gastrectomy without extended nodal resection (Control)
Number of subjects: 34
Study 12172218 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1)
Number of subjects: 25
Study 12172218 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (AT)
Number of subjects: 25
Study 12172218 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA)
Number of subjects: 25
Study 12172218 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (NO-synthase inhibitor)
Number of subjects: 25
Study 12172218 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine (YO)
Number of subjects: 25
Study 12172218 — intervention group
Group type: COMPARATOR
Intervention: Combined pretreatment with L-NMMA and YO
Number of subjects: 25
Study 12172218 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (ETA-antagonist)
Number of subjects: 25
Study 12172218 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-788 (ETB-antagonist)
Number of subjects: 25
Study 11477844 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Shengxue tablet (YSSXT)
Number of subjects: 142
Study 11477844 — intervention group
Group type: COMPARATOR
Intervention: Renshen Guipi Pill (RSGPP)
Number of subjects: 142
Study 7662344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feeding started on the 7th postoperative day
Number of subjects: 35
Study 7662344 — intervention group
Group type: COMPARATOR
Intervention: Oral feeding started on the 14th postoperative day
Number of subjects: 35
Study 2665180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iron supplement containing heme iron and non-heme iron (18-20 mg iron per day) for six months
Number of subjects: 170
Study 2665180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iron supplement containing non-heme iron (18-20 mg iron per day) for six months
Number of subjects: 170
Study 2665180 — intervention group
Group type: EXPERIMENTAL
Intervention: All supplements (including heme and non-heme iron)
Number of subjects: 170
Study 337984 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 0
Study 337984 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 60 mg
Number of subjects: 0
Study 337984 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 0
Study 337984 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol or Morphine (further pain relief)
Number of subjects: 0
Study 30522750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus antispasmodic medication
Number of subjects: 149
Study 30522750 — intervention group
Group type: COMPARATOR
Intervention: Antispasmodic alone
Number of subjects: 149
Study 27037996 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mL of concentrated nitrate-rich beetroot juice (BR)
Number of subjects: 14
Study 27037996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study 26439430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 99
Study 26439430 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 99
Study 26439430 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 99
Study 26439430 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment responders at week 26 follow-up
Number of subjects: 99
Study 26439430 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 99
Study 23786774 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic paracetamol (125 mg or 250 mg suppositories based on body weight) administered at vaccination and at 6-8 hour intervals thereafter
Number of subjects: 301
Study 23786774 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic paracetamol
Number of subjects: 301
Study 23786774 — intervention group
Group type: COMPARATOR
Intervention: Control group (no paracetamol)
Number of subjects: 301
Study 22117715 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumentation with ProTaper Starter Kit (Dentsply/Maillefer) rotary system
Number of subjects: 20
Study 22117715 — intervention group
Group type: COMPARATOR
Intervention: Manual instrumentation using K files (Dentsply/Maillefer) by crown‐down technique, cervical preparation with Gates‐Glidden #1 and #2 burs, and final preparation with ProTaper F2 and F3 rotary files
Number of subjects: 20
Study 19826133 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing intervention
Number of subjects: 264
Study 19826133 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 264
Study 17041859 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-target arm (with enfuvirtide)
Number of subjects: 22
Study 17041859 — intervention group
Group type: COMPARATOR
Intervention: 2-target arm (without enfuvirtide)
Number of subjects: 22
Study 15327448 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg oral misoprostol every 6 h for 48 h
Number of subjects: 153
Study 15327448 — intervention group
Group type: COMPARATOR
Intervention: 50 microg vaginal misoprostol every 6 h for 48 h
Number of subjects: 153
Study 15327448 — intervention group
Group type: COMPARATOR
Intervention: 50 microg vaginal misoprostol
Number of subjects: 153
Study 15327448 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg oral misoprostol
Number of subjects: 153
Study 11125688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 160
Study 11125688 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 1.25 mg
Number of subjects: 160
Study 11125688 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg and Dexamethasone 8 mg
Number of subjects: 160
Study 11125688 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 160
Study 9102248 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 45 ml of NaPh taken at 6 p.m. the day before and at 6 a.m. on the morning of examination
Number of subjects: 486
Study 9102248 — intervention group
Group type: COMPARATOR
Intervention: Group A: 3 liters of PEG solution taken at 2 p.m. the day before examination
Number of subjects: 486
Study 9102248 — intervention group
Group type: COMPARATOR
Intervention: Group B: 45 ml of NaPh solutions taken at 7 a.m. and 7 p.m. the day before examination
Number of subjects: 486
Study 8257144 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of ciprofloxacin (regimen A)
Number of subjects: 14
Study 8257144 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of ciprofloxacin (regimen B)
Number of subjects: 14
Study 8257144 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin (regimen C)
Number of subjects: 14
Study 3929698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate 20 mg (in 2 ml) administered by nebuliser four times daily
Number of subjects: 27
Study 3929698 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study 3929698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate
Number of subjects: 27
Study 30035560 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week somatic-focused culturally adapted cognitive-behavioral therapy (CBT)
Number of subjects: 39
Study 30035560 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 39
Study 28869199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask on (ultrasonic 3D movement analysis with mask)
Number of subjects: 20
Study 28869199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask off (ultrasonic 3D movement analysis without mask)
Number of subjects: 20
Study 27108392 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 60
Study 27108392 — intervention group
Group type: COMPARATOR
Intervention: Conventional tDCS
Number of subjects: 60
Study 27108392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both montages
Number of subjects: 60
Study 27108392 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS during fMRI
Number of subjects: 60
Study 24683571 — intervention group
Group type: EXPERIMENTAL
Intervention: IIPP with SCTG (test group)
Number of subjects: 20
Study 24683571 — intervention group
Group type: COMPARATOR
Intervention: IIPP without SCTG (control group)
Number of subjects: 20
Study 22236813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy flap fixation using fine absorbable sutures
Number of subjects: 40
Study 22236813 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound closure method
Number of subjects: 40
Study 20384660 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month health intervention programme (study circles with diet sessions and physical activities)
Number of subjects: 41
Study 20384660 — intervention group
Group type: COMPARATOR
Intervention: Control programme
Number of subjects: 41
Study 18343247 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/d
Number of subjects: 148
Study 18343247 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg/d
Number of subjects: 148
Study 15969882 — intervention group
Group type: EXPERIMENTAL
Intervention: Device N (Novolizer)
Number of subjects: 0
Study 15969882 — intervention group
Group type: COMPARATOR
Intervention: Device T (Turbuhaler)
Number of subjects: 0
Study 12242325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed (HS) training at 4.73 rad.s(‐1) (knee) and 3.14 rad.s(‐1) (ankle)
Number of subjects: 100
Study 12242325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-speed (LS) training at 1.05 rad.s(‐1) for both joint actions
Number of subjects: 100
Study 12242325 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 100
Study 10858343 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g once daily for 5 days at 20 mg/kg/day)
Number of subjects: 88
Study 10858343 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (200 mg orally twice a day for 5 days at 8 mg/kg/day)
Number of subjects: 88
Study 9105980 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 73
Study 9105980 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Supplemented General Anesthesia (RSGEN)
Number of subjects: 73
Study 8454478 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (50 Gy in 20 fractions in 28 days)
Number of subjects: 212
Study 8454478 — intervention group
Group type: EXPERIMENTAL
Intervention: Split course radiotherapy (25 Gy in 10 fractions in 14 days followed by a 4 week rest and a further 25 Gy in 10 fractions in 14 days) plus concurrent chemotherapy (Mitomycin C on day 1 and day 43, 5FU continuous infusions on days 1‐4 and days 43‐46)
Number of subjects: 212
Study 8454478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (Radiotherapy and Split course radiotherapy plus chemotherapy)
Number of subjects: 212
Study 3697941 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiannual screening by radiologic and sputum cytologic study
Number of subjects: 6364
Study 3697941 — intervention group
Group type: COMPARATOR
Intervention: Screening at a 3-year interval
Number of subjects: 6364
Study 3697941 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 6364
Study 31338789 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional video clip
Number of subjects: 60
Study 31338789 — intervention group
Group type: COMPARATOR
Intervention: Neutral video clip (control group)
Number of subjects: 60
Study 28869160 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed models in educational seminars
Number of subjects: 67
Study 28869160 — intervention group
Group type: COMPARATOR
Intervention: PowerPoint presentation-based educational seminar
Number of subjects: 67
Study 27658693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/Lamivudine (TDF/3TC)
Number of subjects: 0
Study 27658693 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (3TC)
Number of subjects: 0
Study 23551390 — intervention group
Group type: EXPERIMENTAL
Intervention: 60:40 deproteinized bovine bone (DPBB) and autogenous bone (AB) mixture
Number of subjects: 13
Study 23551390 — intervention group
Group type: COMPARATOR
Intervention: 90:10 deproteinized bovine bone (DPBB) and autogenous bone (AB) mixture
Number of subjects: 13
Study 22589472 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 5 mg/kg/d
Number of subjects: 166
Study 22589472 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 10 mg/kg/d
Number of subjects: 166
Study 22589472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 20697801 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with docetaxel, doxorubicin and cyclophosphamide (TAC)
Number of subjects: 2072
Study 18184893 — intervention group
Group type: EXPERIMENTAL
Intervention: ePedsQL (electronic version of the Pediatric Quality of Life Inventory)
Number of subjects: 92
Study 18184893 — intervention group
Group type: COMPARATOR
Intervention: PedsQL paper-and-pencil mode of administration
Number of subjects: 92
Study 16820261 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (5, 10 or 20mg)
Number of subjects: 383
Study 12792554 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management group intervention
Number of subjects: 45
Study 12792554 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet control
Number of subjects: 45
Study 10648326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microg
Number of subjects: 92
Study 10648326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 10 microg
Number of subjects: 92
Study 10648326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 20 microg
Number of subjects: 92
Study 10648326 — intervention group
Group type: COMPARATOR
Intervention: Control (40 mL 1.5% mepivacaine and saline)
Number of subjects: 92
Study 8953335 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial A (3-day pretest, postexercise supplementation + glucose polymers/fructose pretesting + glucose polymers/glucose during testing)
Number of subjects: 8
Study 8953335 — intervention group
Group type: COMPARATOR
Intervention: Trial B (placebo during 3-day pretest + glucose polymers/fructose pretesting + glucose polymers/glucose during testing)
Number of subjects: 8
Study 8953335 — intervention group
Group type: COMPARATOR
Intervention: Trial C (placebo at all time points)
Number of subjects: 8
Study 29200067 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of methylprednisolone administered intravenously 30 minutes before surgery
Number of subjects: 78
Study 29200067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 27138187 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 60 mg (AT60)
Number of subjects: 46
Study 27138187 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg (AT20)
Number of subjects: 46